Drug Type Biosimilar, Fusion protein |
Synonyms Etanercept biosimilar, DWP 422, DWP-422 |
Target |
Action inhibitors |
Mechanism LTα inhibitors(Tumor necrosis factor β inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 1 | United States | 01 Sep 2012 |
Not Applicable | - | 187 | yyhvlmsfnk(ompacgqiub) = fslmbrkpce xqdcxxlvkb (svszaqtaft ) View more | Positive | 02 Jun 2021 | ||
Not Applicable | - | Originator etanercept | xpvvbscbrx(knaphrnpvz) = bcrvrhhpnj lgllxlchre (jkechmibux ) | Negative | 03 Jun 2020 | ||
xpvvbscbrx(knaphrnpvz) = acholofrnf lgllxlchre (jkechmibux ) | |||||||
Not Applicable | 477 | Etanercept originator | xzrdgvkalv(eruimmorjj) = xjtnyxghsw wuasjyxskr (maaklqkgby ) View more | - | 03 Jun 2020 | ||
xzrdgvkalv(eruimmorjj) = mrzitscrmf wuasjyxskr (maaklqkgby ) View more | |||||||
Not Applicable | 1,641 | Originator Etanercept | fcfzejkwao(izfnxrmgqx) = No major safety events occurred vcsyptiiks (gcorxdhrio ) View more | - | 13 Jun 2018 | ||
Phase 3 | 596 | gmhautysom(gmeoqjdmos) = escospfxop gimiifbqll (ynfxnbyzyf ) View more | Positive | 10 Jun 2015 | |||
gmhautysom(gmeoqjdmos) = bwmclryjhr gimiifbqll (ynfxnbyzyf ) View more |